



US009408839B2

(12) **United States Patent**
Lavedan et al.

(10) **Patent No.:** **US 9,408,839 B2**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE**

(71) Applicant: **Vanda Pharmaceuticals, Inc.,**
Washington, DC (US)

(72) Inventors: **Christian Lavedan,** Potomac, MD (US);
Simona Volpi, Derwood, MD (US)

(73) Assignee: **Vanda Pharmaceuticals, Inc.,**
Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/967,276**

(22) Filed: **Dec. 12, 2015**

(65) **Prior Publication Data**

US 2016/0166561 A1 Jun. 16, 2016

Related U.S. Application Data

(60) Continuation of application No. 14/707,477, filed on May 8, 2015, now Pat. No. 9,243,295, which is a division of application No. 13/319,430, filed as application No. PCT/US2010/035045 on May 15, 2010, now Pat. No. 9,057,104.

(60) Provisional application No. 61/178,934, filed on May 15, 2009.

(51) **Int. Cl.**
C12Q 1/68 (2006.01)
A61K 31/454 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/454** (2013.01); **C12Q 1/6883** (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/156** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	2003054226	A2	7/2003
WO	0354226	A3	4/2004
WO	2005007871	A2	1/2005
WO	2005007871	A3	9/2005
WO	2006039663	A2	4/2006
WO	2006039663	A3	11/2006
WO	2008144599	A2	11/2008
WO	2008144599	A3	1/2009
WO	2009036056	A1	3/2009

OTHER PUBLICATIONS

Patent Cooperation Treaty, PCT Notification of Transmittal of The International Search Report and The Written Opinion of the Interna-

tional Searching Authority, or the Declaration for PCT/US2010/035045 dated Nov. 3, 2010, 24 pages.

Kondo et al., "Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients," Sep. 2003, pp. 921-926, Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 27, No. 6 (XP002483913).

Lavedan et al., "Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study," Jun. 2008, pp. 804-819, Molecular Psychiatry, vol. 14, No. 8 (XP002597954).

Lavedan et al., "Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial," Mar. 2008, pp. 289-301, Pharmacogenomics, vol. 9, No. 3 (XP009104913).

Young et al., "Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2* A1 allele," Aug. 2004, pp. 147-151, British Journal of Psychiatry, vol. 185 (XP002483915).

Patent Cooperation Treaty, PCT Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter 1 of the Patent Cooperation Treaty) for PCT/US2010/035045 dated Nov. 24, 2011, 14 pages.

Parsons et al., "A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate," Psychiatric Genetics. 17:159-63 (2007).

Hamilton et al., "Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study," 2009, pp. 804-819, Molecular Psychiatry, vol. 14.

Yasui-Furukori et al., "Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients," 2008, pp. 1491-1495, Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 32.

Kwon et al., "Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole," 2008, pp. 897-907, European Neuropsychopharmacology, vol. 18.

Schafer et al., "Association of Short-Term Response to Haloperidol Treatment with a Polymorphism in the Dopamine D2 Receptor Gene," 2001, pp. 802-804, New York State Library, AJP in Advance. Suzuki et al., "The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients," Pharmacogenetics. 10 (4):335-41 (2000).

Restriction Requirement for U.S. Appl. No. 13/319,430, dated Nov. 27, 2013, 9 pages.

Office Action for U.S. Appl. No. 13/319,430, dated Feb. 21, 2014, 16 pages.

Final Office Action for U.S. Appl. No. 13/319,430, dated Nov. 6, 2014, 10 pages.

Notice of Allowance and Fee(s) Due for U.S. Appl. No. 13/319,430, dated Feb. 17, 2015, 16 pages.

Notice of Allowance and Fee(s) Due for U.S. Appl. No. 14,707,477, dated Sep. 18, 2015, 16 pages.

Primary Examiner — Jehanne Sitton

(74) *Attorney, Agent, or Firm* — Hoffman Warnick LLC

(57) **ABSTRACT**

The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.

14 Claims, 4 Drawing Sheets